Harmony Biosciences Holdings, Inc. (HRMY) Investor Relations Documents

Harmony Biosciences Holdings, Inc. (HRMY) investor relations documents from the company's IR site: 6 presentations, 34 press releases; latest deck 2026-08-04. Read in-app with summaries. First-party data.

Presentation: Harmony Biosciences reported Q2 2026 financial results, achieving record net product revenue of $261.3 million, a 30% increase year-over-year.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-06Press releaseHarmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
2026-08-04Earnings deckPresentation
2026-08-04Press releaseHarmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Re
2026-07-21Press releaseHarmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
2026-07-16Press releaseHarmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and An
2026-06-11Press releaseHarmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
2026-05-27Press releaseHarmony Biosciences to Participate in Upcoming Investor Conferences
2026-05-07PresentationPresentation
2026-05-07Earnings deckCorporate Presentation
2026-05-07Press releaseHarmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2
2026-04-23Press releaseHarmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
2026-04-16Press releaseHarmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurol
2026-04-14Press releaseHarmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
2026-03-31Press releaseHarmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
2026-03-04Press releaseHarmony Biosciences to Participate in Upcoming Investor Conferences
2026-02-24PresentationPresentation
2026-02-24Press releaseHarmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
2026-02-17Press releaseHarmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cat
2026-02-10Press releaseHarmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
2026-01-13Presentation44th Annual J.P. Morgan Healthcare Conference Presentation
2026-01-13Press releaseHarmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Poten
2026-01-07Press releaseHarmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseEarnings Release
Press releaseEarnings Release
2025-05-06Earnings deckHRMY Q1 2025 Earnings Presentation_FINAL.pdf
2025-02-25Press releaseEarnings Release
2024-10-29Press releaseEarnings Release
2024-08-06Press releaseEarnings Release
2024-04-30Press releaseEarnings Release
2024-02-22Press releaseEarnings Release
2023-10-31Press releaseEarnings Release
2023-08-01Press releaseEarnings Release
2023-05-02Press releaseEarnings Release
2023-02-21Press releaseEarnings Release
2022-11-01Press releaseEarnings Release
2022-08-02Press releaseEarnings Release
2022-05-03Press releaseEarnings Release
2022-02-28Press releaseEarnings Release
2021-11-09Press releaseEarnings Release
2021-08-10Press releaseEarnings Release

HRMY overview · HRMY earnings · HRMY financials · HRMY KPIs · HRMY documents · HRMY ownership · HRMY peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.